Appointments at Parexel, Catalent, AMRI, BioStorage and BRANY – People on the move

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Parexel, Catalent, AMRI, BioStorage and BRANY.

Parexel Consulting has hired Edwin Rivera-Martinez as technical vice president (TVP) to its strategic compliance services team. Rivera-Martinez is the former chief of the International Compliance Branch of the US Food and Drug Administration (FDA).

Ludo Reynders has been named as CEO of Premier Research Group. Reynders is the former CEO of AAIPharma and worked at Quintiles for 16 years. He also spent seven years at Bristol-Myers Squibb.

Biomedical Research Alliance of New York (BRANY) has appointed Rich Green as central IRB (institutional review board) business development director. Green will be responsible for marketing IRB services to sponsors.

Nimita Limaye, VP and global head, strategic data services and medical writing at Siro Clinpharm, has been chosen as the incoming chair of the Society for Clinical Data Management (SDCM).

Catalent Pharma Solutions has hired Mark Bridgewater as global account director. Bridgewater was formerly head of global manufacturing services at Wockhardt and has also worked at Patheon, INyX and Celestica.

Brent Atwood has joined BioStorage Technologies as VP of global sales. Atwood has previously worked at LifeWatch AG, Cerner Corporation and Computer Associates.

AMRI has appointed Gabriel Leung to a newly created position on its board of directors. Leung has worked in biopharm for 22 years, holding positions at OSI Pharmaceuticals, Pharmacia and Sterling Drug.

Robert McCune and Richard Limbacher have joined Delta Point as senior consultants. Limbacher has 18 years of pharma experience and McCune previously worked at Takeda.

ReSearch Pharmaceutical Sciences has extended the employment contract of Steven Bell, its EVP, finance and chief financial officer, to April 2011, when it will be renewed for another year. Bell joined RPS in 2003 having previously worked at CareScience and The MRC Group.

Douglas Fuhrer has been appointed as senior director of drug safety at Ricerca Biosciences. Fuhrer has previously worked at Intermune, Threshold Pharmaceuticals and AstraZeneca.